Abstract
The article describes and applies the author's methodology for analyzing and evaluating the innovative activity of global pharmaceutical transnational corporations. The relevance of the analysis is determined by the extremely high social significance of the pharmaceutical industry for the world population, states of the world and pharmaceutical manufacturing companies. Due to the long development cycle of original, innovative medicines and the high cost of clinical trials, this category of products is produced by global transnational corporations that have large production facilities and research laboratories (centers). Original innovative pharmaceutical products are the driving force behind the development of the global pharmaceutical industry, in accordance with this, there is an objective need to develop new tools and mechanisms for analyzing and evaluating the innovative development of the global pharmaceutical industry within the framework of global pharmaceutical transnational corporations. With the help of an integrated approach, a methodology was developed for assessing the innovative activity of the world's transnational corporations according to the selected parameters. Within the framework of the author's methodology, the largest pharmaceutical manufacturing companies that are engaged in innovative developments in the field of pharmaceuticals have been identified. Also, within the framework of the author's methodology, the main indicators were determined to determine the innovative activity of the world's pharmaceutical transnational corporations, such as: the volume and share of investments of the TOP-10 leading pharmaceutical transnational corporations in research and development of innovative pharmaceutical products; the total number of drugs in development by the TOP-10 leading pharmaceutical transnational corporations. Problems in the global pharmaceutical industry associated with providing the population with innovative medicines are identified and analyzed, and author's recommendations for their elimination are proposed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
